All In Biotech

Drug Trial Radar · NCT05267262

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC

Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Jun 15, 2022

Primary completion

May 21, 2025

Study completion Aug 19, 2025

Sponsor

Lead sponsor
River 3 Renal Corp.Industry
Sponsor type
Industry
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Conditions

  • Alport Syndrome
  • Focal Segmental Glomerulosclerosis

Interventions

  • R3R01Drug

    R3R01 administered orally for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (Safety and Tolerability)Time frame: 12 weeks
  2. Assess change in urine creatinine protein ratioTime frame: 12 weeks

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Los Angeles, California

  • Investigative site

    Boca Raton, Florida

  • Investigative site

    Miami, Florida

  • Investigative site

    Riverview, Florida

  • Investigative site

    Atlanta, Georgia

  • Investigative site

    Boston, Massachusetts

  • Investigative site

    Ann Arbor, Michigan

  • Investigative site

    Minneapolis, Minnesota

  • Investigative Site

    Cary, North Carolina

  • Investigative site

    Cleveland, Ohio

  • Investigative site

    Columbus, Ohio

  • Investigative site

    East Providence, Rhode Island

  • Investigative Site

    Dallas, Texas

  • Investigative site

    Houston, Texas

  • Investigative site

    Brussels, Belgium

  • Investigative site

    Liège, Belgium

  • Investigative site

    Paris, France

  • Investigative site

    Göttingen, Germany

  • Investigative site

    Amsterdam, Netherlands

  • Investigative site

    Nijmegen, Netherlands

  • Investigative site

    Leicester, United Kingdom

  • Investigative site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.